

CONSORT 2010 checklist of information to include when reporting a randomised trial*

			Reported on
Section/topic	Item no.	Checklist item	page no.
Title and abstract			
	1a	Identification as a randomised trial in the title	1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT	5-6
		for abstracts)	
Introduction			
Background and	2a	Scientific background and explanation of rationale	7-8
objectives	2b	Specific objectives or hypotheses	8
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	8,10
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	14-15
Participants	4a	Eligibility criteria for participants	9-10

	4b	Settings and locations where the data were collected	15
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they	10-11
		were actually administered	
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they	11-13
		were assessed	
	6b	Any changes to trial outcomes after the trial commenced, with reasons	14-15
Sample size	7a	How sample size was determined	13
	7b	When applicable, explanation of any interim analyses and stopping guidelines	14
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	10
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	10
Allocation	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers),	10
concealment mechanism		describing any steps taken to conceal the sequence until interventions were assigned	
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to	10
		interventions	
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	10
		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	10
Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	13-14

	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	13-14
Results			
Participant flow (a	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and	15 (and fig 1
diagram is strongly		were analysed for the primary outcome	[p39])
recommended)	13b	For each group, losses and exclusions after randomisation, together with reasons	15 (and fig 1
			[p39])
Recruitment	14a	Dates defining the periods of recruitment and follow-up	15
	14b	Why the trial ended or was stopped	15 (for closure
			of sarilumab
			200-mg arm)
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	table 1 (p28-
			33)
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis	fig 1 (p39)
		was by original assigned groups	
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its	16-18, 34-36,
		precision (such as 95% confidence interval)	40-41, 45-51
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing	
		pre-specified from exploratory	

	1
4	

Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	37-38
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	18-20
Generalisability	21	Generalisability (external validity, applicability) of the trial findings	18-21
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	18-21
Other information			
Registration	23	Registration number and name of trial registry	14
Protocol	24	Where the full trial protocol can be accessed, if available	22
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	14, 23

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, noninferiority and equivalence trials, nonpharmacologic treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up-to-date references relevant to this checklist, see <u>www.consort-statement.org</u>.